Dr Wang Chong   MD, MBA, Chartered MCSI

Wang is a physician (endocrinologist) with over 30 years’ experience in the healthcare/lifesciences industry including 20 years’ experience in the financial sector.

He is the former CEO of Osmetech plc and CFO and commercial director of Phytopharm plc, UK premium-listed medical device and biopharmaceutical companies respectively, where he achieved two FDA product approvals and negotiated multi-million pound out-licensing and co-marketing deals with Unilever plc and Schering-Plough Inc. He is also experienced in raising funds for and listing small to mid-cap companies in the UK and has been instrumental in raising over £70 million for small cap companies in recent years.

He is the Head of Corporate Finance at Hobart Capital Markets LLP. Prior to this he was a Partner, Head of Corporate Finance and Fund Manager of New Science Fund at Shard Capital Partners LLP, Head of Lifesciences Corporate Finance at Keith Bayley Rogers & Co (formerly the Walker Crips Group plc) and Lifesciences Analyst at Canaccord Capital Ltd. He has been a NED of Mediwatch plc and Lipoxen plc, AIM-listed medical diagnostic and biopharmaceutical companies respectively, where he chaired the audit and remuneration committees.

Wang graduated with a medical degree from King’s College London and an MBA from London Business School. He is a Chartered Member of the Chartered Institute for Securities & Investment and a Past-President of the Royal Society of Medicine’s Pharmaceutical Medicine & Research Section.

.